Absci 公司
估值 各估值倍数与自身5年区间的对比
同业对比 Biotechnology
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| Absci 公司 (ABSI) | 1.42B | -10.44 | 5.75 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 126.66B | 29.11 | 6.26 | 0.00% |
| Moderna (MRNA) | 87.04B | -27.32 | 12.87 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 81.41B | 19.57 | 2.57 | 0.46% |
| argenx SE (ARGX) | 51.51B | 31.21 | 6.12 | 0.00% |
| BeiGene (ONC) | 41.96B | 65.32 | 8.11 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算8.3%。
合理价值
Absci Corp is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 52% premium over our quantitative fair value estimate of $7.57 per share; however, this estimate should be taken with a pinch of salt due to its extreme uncertainty rating.
The company's lack of profitability decreases our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield falls in the bottom 1% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are overvalued.
Conversely, the company's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 10.6, a core component of leverage, falls in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
经济护城河
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
作者:Quantitative Equity Report
报价时间 2026-10-16 20:02:11 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
Absci 公司 讨论区 0 条评论